MAIA Biotechnology

MAIA Biotechnology's Novel Cancer Drug Ateganosine Receives USAN Approval for NSCLC Treatment

2 months ago

• MAIA Biotechnology has secured USAN Council approval for "ateganosine" as the nonproprietary name for its lead anticancer agent THIO, marking a crucial regulatory milestone. • Ateganosine is a first-in-class telomere-targeting agent in clinical development for advanced non-small cell lung cancer, designed to induce selective cancer cell death and activate immune responses. • The drug works by altering telomeric guanosine in cancer cells and has shown promising results when used sequentially with PD-(L)1 inhibitors, demonstrating tumor regression in advanced cancer models.

Key Trials in Transplant-Ineligible NDMM

4 months ago

Exploring the latest advancements and considerations in the treatment of transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients, focusing on key trials and personalized treatment strategies.

MAIA Biotechnology's THIO Shows Promise in Phase II Lung Cancer Trial; Institutional Investment Increases

4 months ago

• MAIA Biotechnology's lead candidate, THIO, is currently in Phase II clinical trials, evaluating its potential in treating patients with non-small cell lung cancer. • Recent SEC filings reveal that Geode Capital Management LLC increased its stake in MAIA Biotechnology by 22.9% during the third quarter, indicating growing investor confidence. • Greenwich LifeSciences' GP2 immunotherapy is in Phase III clinical trials, aimed at preventing breast cancer recurrences in patients post-surgery. • Institutional investors and hedge funds have shown increased interest in Greenwich LifeSciences, with Geode Capital Management LLC raising its position by 4.6%.

MAIA Biotechnology Advances THIO to Phase 3 for Advanced NSCLC

5 months ago

• MAIA Biotechnology plans to initiate the THIO-104 Phase 3 trial in 2025 to assess THIO in non-small cell lung cancer (NSCLC) patients resistant to checkpoint inhibitors. • The THIO-104 trial will be a multicenter, open-label study comparing THIO sequenced with a checkpoint inhibitor to chemotherapy in a 1:1 randomization of up to 300 patients. • The primary endpoint of the THIO-104 trial is overall survival, with secondary endpoints including disease control rate, overall response rate, and progression-free survival. • THIO is a first-in-class investigational telomere-targeting agent, and MAIA aims for FDA commercial approval following the THIO-104 trial.

MAIA Biotechnology and BeiGene Collaborate to Evaluate THIO in Multiple Cancers

5 months ago

• MAIA Biotechnology and BeiGene enter a clinical supply agreement to assess THIO, combined with tislelizumab, in Phase 2 trials. • The trials will focus on hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), and colorectal cancer (CRC). • Preclinical results showed THIO, combined with CPI, induced potent anti-tumor immune responses and complete responses in various cancer models. • MAIA retains global development and commercial rights to THIO, targeting accelerated FDA approvals for multiple cancer indications.

MAIA Biotechnology Secures Funding to Advance THIO Clinical Trials

5 months ago

• MAIA Biotechnology has announced a private placement of common stock and warrants, expected to generate approximately $950,000 in gross proceeds. • The funding will support the manufacturing of THIO for Phase II clinical trials, advancing its development as a potential cancer therapy. • The private placement involves accredited investors and company directors, signaling internal confidence in MAIA's prospects and THIO's potential. • MAIA Biotechnology secured an additional $2.715 million via private placement to initiate Part C of the Phase II THIO-101 trial.

MAIA Biotechnology's THIO Shows Promising Survival Benefit in Advanced NSCLC

6 months ago

• MAIA Biotechnology's THIO, combined with cemiplimab, demonstrated a median overall survival of 16.9 months in advanced NSCLC patients who failed prior therapies. • The Phase 2 THIO-101 trial data suggests a significant improvement compared to standard-of-care chemotherapy, which typically shows overall survival of 5-6 months. • The trial's findings support MAIA's regulatory strategy, potentially paving the way for accelerated FDA approval of THIO for third-line NSCLC treatment. • THIO's dual mechanism targets telomeric DNA damage and boosts cancer-specific immune responses, offering a novel approach to treating resistant NSCLC.

MAIA Biotechnology and Regeneron Expand Clinical Trial Collaboration for NSCLC Treatment

7 months ago

• MAIA Biotechnology and Regeneron have expanded their clinical supply agreement to further evaluate THIO in third-line NSCLC patients. • The Phase 2 trial, THIO-101, will assess THIO sequenced with cemiplimab (Libtayo®) in patients resistant to prior checkpoint inhibitors and chemotherapy. • MAIA expects to begin enrolling new patients soon and is exploring potential accelerated approval opportunities based on trial outcomes. • Preliminary results from THIO-101 have demonstrated favorable disease control, progression-free survival, and overall response rates.